- Home
- QUCY vs CYCN Comparison
QUCY vs CYCN Comparison
Compare QUCY & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QUCY | CYCN |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | Germany | United States |
| Employees | 13 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | QUCY | CYCN |
|---|---|---|
| Price | $0.51 | $2.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 346.5K | ★ 8.7M |
| Earning Date | 03-31-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $74.34 | N/A |
| Revenue Next Year | $171.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $1.03 |
| 52 Week High | $0.74 | $8.48 |
Technical Indicators
Market Signals| Indicator | QUCY | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 52.69 |
| Support Level | $0.43 | $2.14 |
| Resistance Level | $0.53 | $3.73 |
| Average True Range (ATR) | 0.07 | 0.33 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 28.54 | 15.10 |
Price Performance
Historical ComparisonAbout QUCY Mainz Biomed N.V. Ordinary Shares
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.